Her2 and Trastuzumab in Breast Cancer

Slamon D.J. , Godolphin W. , Jones L.A. . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707–712.

Pauletti G. , Dandekar S. , Rong H. . Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18: 3651–3664.

Elledge R.M. , Green S. , Ciocca D. . HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998; 4: 7–12.

Berry D.A. , Muss H.B. , Thor A.D. . HER-2-neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000; 18: 3471–3479.

Thor A.D. , Berry D.A. , Budman D.R. . erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998; 90: 1346–1360.

Vogel C. , Cobleigh M. , Tripathy D. . First-line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Annu Meet Am Soc Clin Oncol. 2000; 19: 275a.

Norton L. , Slamon D. , Leyland-Jones B. . Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2+) metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 483a.

Herceptin (Trastuzumab) prescription product insert. South San Francisco, CA: Genentech Inc; revised September 2000.

Mass R.D. , Sanders C. , Charlene K. . The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Annu Meet Am Soc Clin Oncol. 2000; 19: 291a.

Cobleigh M.A. , Vogel C.L. , Tripathy D. . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17: 2639–2648.

Fornier M. , Seidman A.D. , Esteva F.J. . Weekly (W) Herceptin (H) + 1-hr taxol (T): Phase II study in HER2 overexpressing (H2+) and non-expressing (H2–) metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 482a

Burstein H.J. , Kuter I. , Richardson P.G. . Herceptin and vinorelbine for HER2-positive metastatic breast cancer: a phase II study. Proc Annu Meet Am Soc Clin Oncol. 2000: 392a.

Burris HA III , Hainsworth J.D. , Miranda F.P. . Phase II trial of Herceptin induction followed by combination therapy with paclitaxel and carboplatin: a Minnie Pearl Research Network Trial. Proc Annu Meet San Antonio Breast Cancer Symposia. 2000.

Kuzur M.E. , Albain K.S. , Huntington M.O. . A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Annu Meet Am Soc Clin Oncol. 2000: 512a.

Nicholson B.P. , Thor A.D. , Goldstein L.J. . Weekly docetaxel (D) and rhumabher2 (H) combination therapy as first- or second-line treatment for metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol. 2000: 549a.

Malik U. , Sparano J.A. , Manalo J. . Phase II trial of weekly docetaxel (Taxotere) alone or in combination with trastuzumab (Herceptin) in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 2000: 586a.

Lipton A. , Ali S.M. , Leitzel K. . Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 2000; 19: 274a.

Johnston S.R.D. , Hickish T. , Ellis P.A. . Clinical activity with the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer: relationship with tumor type. Proc Annu Meet San Antonio Breast Cancer Symposia. 2000.

Sledge G. , Miller K. , Novotny W. . A phase II trial of single-agent Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol. 2000; 19: 5c.

Fleming G.F. , Meropol N.J. , Hollis D.R. . Phase 1 trial of recombinant human anti-HER2 monoclonal antibody (H) plus low-dose interleukin-2 (IL-2) in patients with solid tumors. Proc Annu Meet Am Soc Clin Oncol. 1999; 18: 710a.

Anderson N.G. , Ahmad T. , Chan K.C. . Effects of ZD1839 (Iressa), a novel EGF preceptor tyrosine kinase inhibitor on breast cancer cell proliferation and invasive-ness. Proc Annu Meet San Antonio Breast Cancer Symposia. 2000.

Herceptin (Trastuzumab) “Dear Doctor” letter. South San Francisco, CA: Genentech Inc; May 3, 2000.

Tripathy D. , Slamon D. , Leyland-Jones B. . Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial. Proc Annu Meet San Antonio Breast Cancer Symposia. 2000: 25a.